NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast, where he discussed the company’s mission to revolutionize antiviral treatment through its nanoviricide platform and highlighted progress of lead drug candidate NV-387. During the interview, Dr. Diwan explained how nanoviricides are designed to prevent viral escape, function independently of patient immune status, and offer broad-spectrum potential across patient populations, from infants to geriatrics. He noted that NV-387 has demonstrated efficacy against multiple unrelated viruses in lethal animal models, including Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, and has completed a Phase I clinical trial with no reported adverse events. Dr. Diwan added that a Phase II clinical trial for NV-387 targeting MPox is ready to begin in the Democratic Republic of Congo following regulatory clearance, positioning the candidate as a potential empirical therapy for acute respiratory and other viral infections with an estimated market opportunity exceeding $17 billion by 2030. To view the full press release, visit https://ibn.fm/EqHoV.
The company’s nanoviricide technology represents a novel approach to antiviral therapy, using specially designed nanomaterials that mimic host cell receptors to bind and neutralize viruses. Unlike traditional antivirals that target specific viral proteins, nanoviricides are designed to be broad-spectrum, potentially effective against a wide range of viruses. This is particularly important in the context of emerging viral threats and the need for treatments that can be deployed rapidly without waiting for pathogen identification. NV-387’s ability to protect against multiple viruses in animal models suggests it could serve as a first-line therapy for respiratory infections and other viral diseases, reducing the burden on healthcare systems during outbreaks.
The completion of a Phase I trial with no adverse events is a significant milestone, indicating a favorable safety profile. The upcoming Phase II trial in the DRC for MPox is a critical step toward regulatory approval and commercialization. MPox has been a growing concern, with outbreaks in Africa and sporadic cases globally. If successful, NV-387 could become an important treatment option, especially in regions with limited healthcare infrastructure. The company estimates the market opportunity for such a broad-spectrum antiviral could exceed $17 billion by 2030, driven by the need for effective therapies against respiratory viruses like RSV, influenza, and coronaviruses, as well as neglected diseases like MPox.
For more information about NanoViricides, visit https://www.nanoviricides.com. The latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
